Results 141 to 150 of about 2,212 (184)

Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis

open access: yesNew England Journal of Medicine, 2021
Background: Interleukin-1 has been implicated as a mediator of recurrent pericarditis. The efficacy and safety of rilonacept, an interleukin-1α and interleukin-1β cytokine trap, were studied previously in a phase 2 trial involving patients with recurrent
Fang Fang, Allan Klein, Sushil A Luis
exaly   +8 more sources

Longitudinal Cardiac Magnetic Resonance Imaging Following Clinical Response to Rilonacept and Prior to Recurrence Upon Treatment Suspension: A RHAPSODY Subgroup Analysis [PDF]

open access: yesEuropean Heart Journal Cardiovascular Imaging
AIMS: In the Phase 3 trial, RHAPSODY, rilonacept effectively resolved active pericarditis recurrences, and long-term treatment led to sustained pericarditis recurrence risk reduction.
John F Paolini   +2 more
exaly   +3 more sources

Rilonacept for the Treatment of Recurrent Pericarditis

Expert Opinion on Biological Therapy, 2022
Recurrent pericarditis (RP) is a debilitating disease that has an underlying autoinflammatory pathophysiology mediated by cytokine interleukin (IL)-1. Rilonacept, a recombinant dimeric fusion protein that blocks IL-1α and IL-1β signaling has emerged as a valuable therapeutic option of RP.
Reza Reyaldeen   +2 more
exaly   +3 more sources

Rilonacept (Interleukin-1 Inhibition) for the Treatment of Pericarditis [PDF]

open access: yesCurrent Cardiology Reports, 2022
We reviewed the contemporary literature and clinical trials to discuss the applications of the interleukin-1 (IL-1) inhibitor rilonacept to treat pericarditis, with regards to pathophysiology, pharmacology, efficacy, and safety.Rilonacept is an emerging novel agent for treating recurrent pericarditis, with phase II and III clinical trials recently ...
Tom Kai Ming Wang, Allan Klein
exaly   +3 more sources

Rilonacept

Nature Reviews Drug Discovery, 2008
Hal M Hoffman   +2 more
exaly   +2 more sources

Rilonacept use in lupus pericarditis

Clinical and Experimental Rheumatology, 2023
Lupus pericarditis affects 22% of patients with systemic lupus erythematosus (SLE), is associated with worse outcomes, and often requires immunosuppression. Rilonacept is an interleukin-1 receptor antagonist approved for the treatment of recurrent idiopathic pericarditis, but its efficacy in lupus pericarditis is unknown.
Andrea, Fava   +2 more
openaire   +2 more sources

Rilonacept—CAPS and Beyond

Annals of the New York Academy of Sciences, 2009
Rilonacept is a dimeric fusion protein consisting of the extracellular domains of interleukin (IL)‐1 type 1 receptor and IL‐1 receptor accessory protein joined to the constant region (Fc) of human immunoglobulin G1. By incorporating both components of the IL‐1 binding complex, rilonacept is able to tightly bind IL‐1 with picomolar affinity.
Neil Stahl, Allen Radin
exaly   +2 more sources

Home - About - Disclaimer - Privacy